Agios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer and rare genetic metabolic disorders. Founded in 2007 and based in Cambridge, Massachusetts, Agios specializes in precision medicine strategies, aiming to improve outcomes for patients through innovative small-molecule drugs. The company's portfolio includes treatments targeting metabolic pathways fundamental to cancer cell growth and survival.
Company News
Agios Pharmaceuticals received a positive opinion from the European Medicines Agency for PYRUKYND, a treatment for thalassemia in adults. The drug shows promise in treating anemia associated with alpha- and beta-thalassemia, with a final European Commission decision expected in early 2026.
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
A Wall Street analyst who was an early proponent of GenAI says investors are facing a "trough of disillusionment," surrounding Nvidia, other companies.
Get the latest financial updates and insights with Wall Street Breakfast's daily podcast available on Seeking Alpha, iTunes, and Spotify.
RBC Capital has decided to maintain its Outperform rating of Agios Pharmaceuticals (NASDAQ:AGIO) and raise its price target from $40.00 to $42.00. Shares of Agios Pharmaceuticals are trading up 0.93% over the last 24 hours, at $27.73 per share. A move to $42.00 would account for a 51.49% increase from the current share price. About Agios Pharmace...